Shionogi (TYO:4507) said Taiwan's Food and Drug Administration accepted the new drug application for ensitrelvir fumaric acid submitted by its Taiwanese subsidiary.
A contract for purchasing ensitrelvir for government stockpiling was also finalized with the Taiwan Centers for Disease Control, according to a Wednesday bourse filing.
Ensitrelvir is an oral antiviral that inhibits SARS-CoV-2 replication, and while it has full approval in Japan and special access in Singapore, it remains investigational elsewhere.
Price (JPY): $2263.00, Change: $+31, Percent Change: +1.39%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.